IO, Jakarta – Daewoong Pharmaceutical, a South Korean global healthcare company, is committed to developing a biopharmaceutical business in Indonesia. This signifies transforming Indonesia into a center of the biopharmaceutical industry. Other than its social contributions and HR development programs, Daewoong Pharmaceutical also brings in advanced technological breakthroughs from its native country and cooperates with local pharmaceutical businesses.
Officially entering Indonesia by establishing a branch office in 2005, Daewoong Pharmaceutical linked up with Indonesia’s Infion and established a joint venture, “Daewoong Infion” in 2012, with the first biopharmaceutical factory in Indonesia, i.e. in Surabaya, East Java. Daewoong Infion is in the front line of the strategy to execute the Company’s vision of being the base for a sophisticated bio-technology business that does its part in propelling the development of a bio-industry in Indonesia.
Daewoong Infion’s President Director, Suh Chang-woo, stated that in the future, Daewoong Infion will be more than just a medical supplier. It will actively perform cooperative research and clinical tests on new bio-medicines, through open collaboration with Indonesia’s most credible research agencies and universities, including the University of Indonesia and Bandung Institute of Technology (ITB). “We naturally hope that by developing products that are suitable for Indonesia, we can truly contribute to the improvement of Indonesians’ quality of life, by providing the best and safest drugs at affordable prices,” he said.
One of the milestones in Daewoong Infion’s journey is the distribution of Epodion, the first bio-similar drug in Indonesia that won an award from the Ministry of Health. Daewoong Infion itself was nominated as the best biopharmaceutical company by the Food and Drug Control Agency of Indonesia (Badan Pengawasan Obat dan Makanan – “BPOM”) in 2017. Epodion, the Erythropoietin (EPO) produced and sold Daewoong Infion, is a medication to treat anemia through dialysis of chronic kidney failure patients and cancer patients. Epodion obtained its medical product distribution permit from BPOM Indonesia in December 2016 and it was released to the market in April 2017. Within six months after its launch, Epodion ranked no. 1 in Indonesia’s EPO market. It is currently the market leader with a market share of more than 40%.
To complement this success, Daewoong Infion is currently preparing to obtain the halal certification for Epodion. The certificate, prepared since the factory in Surabaya was first established, is now in the final stages of evaluation. So far, just about no biopharmaceutical products have obtained the halal certification. In order to achieve the certification, a product must undergo a series of tough tests. If Epodion succeeds in obtaining this certification, it will be the first animal-cell derivative product in the world to do so, and it will become exemplars for similar drugs in the future to get halal certification. With the halal certificate in hand, Daewoong Infion plans to expand to the Middle Eastern market, which has a potential market scale value of IDR 300 billion.
Other than Epodion, Daewoong Infion provides quality biopharmaceutical products such as EGF (Epidermal Growth Factor), Caretropin, vaccines, etc. for the Indonesian public.
Research and technology for EGF started in 1992. Three years later, Daewoong Pharmaceutical succeeded in developing the technology required for mass producing EGF, and it was marketed in 2001. The structure of Daewoong’s EGF is highly similar to natural EGF in the human body. EGF was then nominated as the number one new bio-medicine in South Korea.
Daewoong Infion is currently making an effort to develop and produce EGF in its own factories, in order to allow mass distribution of the drug in Indonesia by mid-2020. Indonesia and Korea are collaborating in researching and developing an all-in-one mold to support EGF production. Clinical tests are being performed in order to obtain expansion of EGF’s medical indication. This would help it become the no. 1 bio-medicine in Indonesia, as well as allowing EGF to be exported.
EGF has a similar use with Easyef External Solution, which is effective for treating diabetic foot ulcers, by healing the skin and helping it grow. EES is formulated as a jet spray liquid that can be used to treat injured skin without touching it directly. Its sister product, the Easyef Ointment, is easily spread out on the skin without any size limit of the injured area. Both are used for treating various types of acute injuries that are hard to heal.
Another Daewoong Pharmaceutical star is Caretropin, which was launched in 2008. It is meant to help patients with low hormonal growth rates. This is generally an expensive treatment that patients tend to skip. Therefore, Daewoong Pharmaceutical developed Caretropin through Daewoong Infion in order to allow Indonesians to enjoy hormonal treatment at a more affordable cost. (dsy)